Process Excellence & Pharma Market | Pharma-IQ, Division of IQPC

Pharmaceutical Firms Make Immunogenicity a Priority

Tue, 08 Jun 2010 04:00:00 GMT

In terest in immunogenicity is growing among pharmaceutical companies. The concept

Nanotechnology Puts Drug Solubility Under the Microscope

Fri, 04 Jun 2010 04:00:00 GMT

One aspect of solubility which continues to get much attention is nanotechnology. The

Does the Future of Solubility Lie in HME?

Fri, 04 Jun 2010 04:00:00 GMT

When it comes to drug development, pharmaceutical firms face a number of difficult

The Technological Approach to Immunogenicity

Pharma IQ — Wed, 12 May 2010 04:00:00 GMT

When it comes to drug development, immunogenicity is one concept that has risen up the

Compound Management Becomes Big Business

Pharma IQ — Wed, 12 May 2010 04:00:00 GMT

In the world of pharmaceuticals, few issues are more important than compound management

Asthma Insights with Matthew Catley

Matthew Catley — Thu, 29 Apr 2010 04:00:00 GMT

Matthew Catley, Head of Respiratory Pharmacology, UCB, provides some insights into

Pharma Companies Looking to the East for CRO Prospects

Pharma IQ — Tue, 16 Mar 2010 04:00:00 GMT

The emerging trend for pharmaceutical companies to increase their efforts to outsource

Polymorphism and Crystallisation 2010: An Interview with Martin Wijaya Hermanto

Martin Wijaya Hermanto — Tue, 16 Mar 2010 04:00:00 GMT

Poster Awards Session Finalist: Martin Wijaya Hermanto IQPC: Hi, Martin. Tell us a bit

Drug Discovery and the Market Today Part 4: Developing Amorphous Forms

Fri, 11 Jun 2010 04:00:00 GMT

Dr. David Elder, the Externalization Director for GlaxoSmithKline, talks exclusively to

Drug Discovery and the Market Today Part 5: Considering Genotoxic and Carcinogenic Impurities

Fri, 11 Jun 2010 04:00:00 GMT

Dr. David Elder, the Externalization Director for GlaxoSmithKline, talks exclusively to

Drug Discovery and the Market Today: Video Exclusive with Dr. David Elder, GSK

Fri, 11 Jun 2010 04:00:00 GMT

Dr. David Elder, the Externalization Director for GlaxoSmithKline, talks exclusively to

Drug Discovery and the Market Today Part 2: Critical Thoughts on Stability

Wed, 09 Jun 2010 04:00:00 GMT

Dr. David Elder is the Externalization Director for GlaxoSmithKline. Here, he talks

Drug Discovery and the Market Today Part 3: The Focus on Solubility

Wed, 09 Jun 2010 04:00:00 GMT

Dr. David Elder is the Externalization Director for GlaxoSmithKline. Here, he talks

Drug Discovery and the Market Today Part 1: An Overview of Externalisation in the Pharma Industry

Tue, 08 Jun 2010 04:00:00 GMT

Dr. David Elder is the Externalization Director for GlaxoSmithKline. Here, he talks

Engineering Cocrystal Solubility and Streamlining Cocrystal Selection

Thu, 27 May 2010 04:00:00 GMT

How is cocrystal solubility influenced by solution chemistry? How to assess cocrystal

Effective Methods of Amorphous Particle Engineering and Downsizing the Amorphous Form

Thu, 27 May 2010 04:00:00 GMT

Spray Drying Melt extrusion Cryo-grinding Supercritical Fluid Technology

Characterisation of Composite Materials Containing Amorphous/Nanocrystalline Phases

Thu, 27 May 2010 04:00:00 GMT

Drug-polymer composites key concepts Physical-chemical characterization techniques

Development and Validation of a Drug Product Solid State Method for a NDA

Thu, 27 May 2010 04:00:00 GMT

Background on SAPHRIS® (asenapine) Why a solid state method had to be developed FDA

Enhancing the Drug Development Strategy for Pharmaceutical Co-crystals

Wed, 26 May 2010 04:00:00 GMT

Why is strategic enhancement needed? The discovery - development continuum Form

Cultivating Co-Crystals: From Crystal Engineering to Crystal Growth and Back...

Wed, 26 May 2010 04:00:00 GMT

Which co-formers will successfully form a new phase? Does the new phase give suitable

Structure-Property Relationships in Multiple Component Crystalline Solids

Wed, 26 May 2010 04:00:00 GMT

Does solid-state chemistry offer a low-cost, low-risk and high reward paradigm for drug

SME Case Study: Improving Throughput of Compound Handling, Quality of Compounds and Flexibility of Service

Wed, 19 May 2010 04:00:00 GMT

Siena Biotech Background. The Corporate Compound Collection. Compound Management &

Quality Control and Concentration Determination of Compound Libraries by Combined NMR and LC-UV-MS Analytics

Tue, 18 May 2010 04:00:00 GMT

Technologies and Workflow for Quality Control of Compound Libraries at Roche Basel.

Practical Realities of Using a High Throughput Cherry Picking (HTCP) Module to Support New Screening

Tue, 18 May 2010 04:00:00 GMT

The HTCP System: Generalities. Integration of the new system in the HTS workflow.

Building Experimental and Predictive Technologies into a Strategy for Progressing Poorly Soluble Drugs to the Patient

Mon, 17 May 2010 04:00:00 GMT

Formulation considerations in discovery and development: focus will be on orally

ELN Architectures and Cross Domain Support

Wed, 24 Feb 2010 05:00:00 GMT

The demands on ELNs are diverse, and to keep ahead of constant advancements in the

An Interview with Dr. Adam Friedman

Wed, 10 Mar 2010 05:00:00 GMT

An interivew with Dr. Adam Friedman, Chief Resident at the Department of Dermatology at

Antimicrobial Drug Development � The Past, the Present, and the Future

Wed, 10 Mar 2010 05:00:00 GMT

Antimicrobial resistance has been an issue since the introduction into clinical use of

Development of Drugs for Antimicrobial-Resistant Pathogens

Wed, 10 Mar 2010 05:00:00 GMT

Clinicians have noted an association between antimicrobial resistance and antimicrobial

An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals

Wed, 10 Mar 2010 05:00:00 GMT

An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium

Prospects for the Next Anti-Pseudomonas Drug

Wed, 10 Mar 2010 05:00:00 GMT

Pseudomonas aeruginosa is one of the most dreaded Gramnegative bacterial pathogens in

Oral Rotavirus Vaccines: How Well Will They Work

Wed, 10 Mar 2010 05:00:00 GMT

Rotavirus vaccines hold promise to decrease the burden of severe diarrhea in the poorest